Charles River Laboratories International (MIL:1CRL) Current Deferred Revenue: €168 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1CRL Charles River Laboratories International Inc MIL:1CRL
71 GF Score
Price €143.90
GF Value €120.74
! 8 Warning Signs
View Full Analysis

What is Charles River Laboratories International Current Deferred Revenue?

Charles River Laboratories International MIL:1CRL 71 Current Deferred Revenue is €168 Mil as of Mar. 2026. GuruFocus rates MIL:1CRL with a GF Score™ of 71/100 and a GF Value™ of €120.74. The stock has 8 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Charles River Laboratories International's current deferred revenue for the quarter that ended in Mar. 2026 was €168 Mil.

Charles River Laboratories International Current Deferred Revenue Related Terms

Charles River Laboratories International Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Charles River Laboratories International's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Charles River Laboratories International Current Deferred Revenue Chart

Charles River Laboratories International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 194.44 249.46 221.75 237.15 179.70

Charles River Laboratories International Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 231.68 232.65 202.54 179.70 168.10
MIL:1CRL
71GF Score
Charles River Laboratories International Inc MIL:1CRL
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €168 Mil mean?
Charles River Laboratories International (MIL:1CRL) has a Current Deferred Revenue of €168 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Charles River Laboratories International and its competitors.
Is Charles River Laboratories International's Current Deferred Revenue too high?
Charles River Laboratories International's current Current Deferred Revenue is €168 Mil. Overall, Charles River Laboratories International has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's Current Deferred Revenue compare to RVTY and ICLR?
Charles River Laboratories International's Current Deferred Revenue of €168 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Diagnostics & Research company?
A good Current Deferred Revenue depends on the Medical Diagnostics & Research industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Charles River Laboratories International and its competitors. Charles River Laboratories International's current Current Deferred Revenue is €168 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Charles River Laboratories International (MIL:1CRL) has a current Current Deferred Revenue of €168 Mil. The stock's GF Value™ is €120.74, compared to a current price of €143.90 — trading 19.2% above its estimated fair value. The current Current Deferred Revenue is €168 Mil. Charles River Laboratories International's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Charles River Laboratories International (MIL:1CRL), the current Current Deferred Revenue is €168 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Charles River Laboratories International (MIL:1CRL) Overvalued in 2026?

Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued. The current stock price of €143.90 is trading 19.2% above its estimated GF Value™ of €120.74.

Key valuation signals for MIL:1CRL:

  • Current Deferred Revenue: €168 Mil
  • GF Value™: €120.74 vs. price of €143.90 (19.2% above fair value)
  • GF Score™: 71/100 with 8 warning signs

No single metric tells the full story. See the MIL:1CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Charles River Laboratories International Business Description

Other Exchanges CRL:USARV6:Germany
Address 251 Ballardvale Street, Wilmington, MA, USA, 01887
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
71GF Score

Get the complete analysis for MIL:1CRL

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€143.90
Price
€120.74
GF Value